

Express Mail No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: CAPON *et al.*

Confirmation No.: 9053

Application No.: 09/126,559

Group Art Unit: 1648

Filed: July 30, 1998

Examiner: Z. Lucas

For: COMPOSITIONS AND METHODS
FOR DETERMINING ANTI-VIRAL
DRUG SUSCEPTIBILITY AND
RESISTANCE AND ANTI-VIRAL
DRUG SCREENING

Attorney Docket No.: 011068-043-999

JUN 10 2004
TECH CENTER 1600/2300

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application. This paper is being filed pursuant to C.F.R. § 1.34.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☒ Each U.S. patent application publication and U.S. and foreign patent;

☒ Each publication or that portion which caused it to be listed on the PTO-1449;

☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

☐ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☒ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

06/09/2004 SSANDARA 00000011 503013 09126559

01 FC:1806

170.00 DA

CAJD: 502875.1

- ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- ☐ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
- ☒ to be charged to Jones Day Deposit Account No. 503013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Jones Day Deposit Account No. 503013.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)


- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application, and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- (Check Item 8a, 8b, or 8c)*
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 503013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: June 3, 2004


David Pauling for
Nikolaos C. George (Reg. No. 39,201)
JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

P-56056
(Reg. No.)



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
11068-043-999

APPLICATION NO
09/126,559

APPLICANT
Capon et al.

FILING DATE
July 30, 1998

GROUP
1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE
	A01	4,952,496	8/1990	Studier <i>et al.</i>			
	A02	5,126,251	6/1992	Moss <i>et al.</i>			
	A03	5,135,855	8/1992	Moss <i>et al.</i>			
	A04	5,354,674	10/1994	Hodgson			
	A05	5,462,873	10/1995	Garfinkel <i>et al.</i>			
	A06	5,837,464	11/1998	Capon <i>et al.</i>			
	A07	5,874,565	2/1999	Rice <i>et al.</i>			
	A08	6,033,902	3/2000	Haseltine <i>et al.</i>			
	A09	6,242,187	6/2001	Capon <i>et al.</i>			
	A10	20020034732	3/2002	Capon <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A11	WO91/19798	12/1991	PCT				
	A12	WO92/07943	5/1992	PCT				
	A13	WO94/19478	9/1994	PCT				
	A14	WO94/29438	12/1994	PCT				
	A15	WO95/22622	8/1995	PCT				
	A16	WO99/06597	2/1999	PCT				
	A17	International Search Report PCT/US97/01609	4/1997	PCT				
	A18	International Search Report PCT/US98/15967	10/1998	PCT				
	A19	International Search Report PCT/US2003/013791	4/2004	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A20	Alam <i>et al.</i> , "Reporter Genes: Application to the Study of Mammalian Gene Transcription," (1990), Analytical Biochemistry 188:245-254.
	A21	Bernard, "Positive Selection of Recombinant DNA by CcdB," (1996), Biotechniques 21:320-323.
	A22	Blight <i>et al.</i> , "Efficient Initiation of HCV RNA Replication in Cell Culture," (2000), Science 290:1972-1974
	A23	Chalfie, "Green Fluorescent Protein," (1995), Photochemistry and Photobiology, 62:651-656.
	A24	Cheng <i>et al.</i> , "Specific Interaction Between the Hepatitis C Virus Ns5B RNA Polymerase and the 3' End of the Viral RNA," (1999), J. Virol. 73:7044-7049.

A25	Chowrira <i>et al.</i> , "In Vitro and in Vivo Comparison of Hammerhead Hairpin, and Hepatitis Delta Virus Self Processing Ribozyme Cassettes," (1994), J. Biol. Chem. 269: 25856-25864.
A26	Chung <i>et al.</i> , "Hepatitis C Virus Replication is Directly Inhibited By IFN- α in a Full Length Binary Expression System," (2001), 98:9847-9852.
A27	Frese <i>et al.</i> , "Interferon- γ Inhibits Replication of Subgenomic and Genomic Hepatitis C Virus RNAs," (2002), Hepatology 35:694-703.
A28	Gould <i>et al.</i> , "Firefly Luciferase as a Tool in Molecular and Cell Biology," (1988), Analytical Biochemistry 175:5-13.
A29	Grakoui <i>et al.</i> , "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites," (1993), J. Virol. 67:2832-2843.
A30	Guo <i>et al.</i> , "Effect of Alpha Interferon on the Hepatitis C Virus Replicon," (2001) J. Virol. 75:8516-8523.
A31	Hiramatsu <i>et al.</i> , "HCV cDNA Transfection to HepG2 Cells," (1997), J. Viral Hepatol., 4(suppl.1):61-67.
A32	Hoshida <i>et al.</i> , "Improvement of Chemosensitivity Prediction by Transcriptional Profiling in Hepatoma Cells," (2001), Genome Informatics 12:257-58
A33	Ikeda <i>et al.</i> , "Selectable Subgenomic and Genome-Length Dicistronic RNAs Derived from an Infectious Molecular Clone of the HCV-N Strain of Hepatitis C Virus Replicate Efficiently in Cultured Huh7 Cells" (2002) J. Virol. 76:2997-3006.
A34	Kawai <i>et al.</i> , " α -Fetoprotein-Producing Hepatoma Cell Lines Share Common Expression Profiles of Genes in Various Categories Demonstrated by cDNA Microarray Analysis" (2001), Hepatology 33:676-691.
A35	Krieger <i>et al.</i> , "Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations," (2001), J Virol 75:4614-24.
A36	Lohmann <i>et al.</i> , "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line" (1999), Science, 285:110-113.
A37	Lohmann <i>et al.</i> , "Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation," (2001), J. Virol. 75:1437-1449.
A38	Mizutani <i>et al.</i> , "Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2," (1996), J. Virol. 70:7219-7223
A39	Moore <i>et al.</i> , "The Development of β -Lactamase as a Highly Versatile Genetic Reporter for Eukaryotic Cells," (1997) Analytical Chemistry 247:203-209.
A40	Mulligan <i>et al.</i> , "Expression of a Bacterial Gene In Mammalian Cells," (1980), Science 209: 1422-1427.
A41	Olesen <i>et al.</i> , "Detection of β -Galactosidase and β -Glucuronidase Using Chemiluminescent Reporter Gene Assays," Methods in Molecular Biology, Recombinant Protein Protocols: Detection and Isolation, 63:61-70.
A42	Perotta <i>et al.</i> , "A Pseudoknot-Like Structure Required for Efficient Self-Cleavage of Hepatitis Delta Virus RNA," (1991), Nature 350:434-436.
A43	Pflugheber <i>et al.</i> , "Regulation of PKR and IRF-1 During Hepatitis C Virus RNA Replication," (2002), PNAS 99: 4650-4655.
A44	Pietsch, <i>et al.</i> , "Characterization of the Continuous Cell Line HepT1 Derived from a Human Hepatoblastoma," (1996), Lab Invest 74:809-818.
A45	Pietschmann <i>et al.</i> , "Persistent and Transient Replication of Full Length Hepatitis C Virus Genomes in Cell Culture," (2002), J. Virol. 76:4008-4021.
A46	Schenborn <i>et al.</i> , "Reporter Gene Vectors and Assays," (1999), Molecular Biotechnology 13:29-44.
A47	Shimizu <i>et al.</i> , "Neutralizing Antibodies Against Hepatitis C Virus and the Emergence of Neutralization Escape Mutant Viruses," (1994), J. Virol. 68:1494-1500.
A48	Shimizu <i>et al.</i> , "Multicycle Infection of Hepatitis C Virus in Cell Culture and Inhibition by Alpha and Beta Interferons," (1994), J. Virol. 68:8406-8408.
A49	Shimizu <i>et al.</i> , "Correlation Between the Infectivity of Hepatitis C Virus <i>In Vivo</i> and its Infectivity <i>In Vitro</i> ," (1993), PNAS 90:6037-6041.
A50	Shimizu <i>et al.</i> , "Evidence for <i>In Vitro</i> Replication of Hepatitis C Virus Genome in a Human T-Cell Line," (1992) , PNAS 89:5477-5481.

JUN 03 2004

A51

Southern *et al.*, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," (1982), J. Molec. Appl. Genet. 1:327-341.

A52

Steinkühler *et al.*, "Activity of Purified Hepatitis C Virus Protease NS3 on Peptide Substrates," (1996), J. Virol. 70:6694-6700.

A53

Sugden *et al.*, "A Vector that Replicates as a Plasmid and can be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus," (1985), Mol. Cell. Biol. 5, 410-413.

A54

Valli *et al.*, "Hepatitis C Virus Infection of a Vero Cell Clone Displaying Efficient Virus-Cell Binding," (1997), Res. Virol. 148:181-186.

A55

Vassilev *et al.*, "Authentic and Chimeric Full-Length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yield Infectious Transcripts," (1997), J. Virol. 71:471-478

A56

Wadkins *et al.*, "Ribozyme Activity in the Genomic and Antigenomic RNA Strands of Hepatitis Delta Virus," (2002), Cell Mol. Life Sci. 59:112-25.

A57

Witherell *et al.*, "Statistical Analysis of Combined Substitutions in Nonstructural 5A Region of Hepatitis C Virus and Interferon Responses," (2001), J. Med. Virol. 63:8-16.

A58

Wright-Minogue *et al.*, "Cross-Genotypic Interaction Between Hepatitis C Virus NS3 Protease Domains and NS4A Cofactors," (2000), J. Hepatology 32:497-504.

A59

Yang *et al.*, "Quantification of Gene Expression with a Secreted Alkaline Phosphatase Reporter System," (1997), BioTechniques 23:1110-1114.

A60

Yoo *et al.*, "Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected With HCV," (1995), 69:32-38.

A61

Zlokarnik, "Fusions to β -Lactamase as a Reporter for Gene Expression in Live Mammalian Cells," (2000), Methods in Enzymology 326:221-241.

A62

Danos, Olivier and Mulligan, Richard C. "Safe and Efficient Generation of Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges" Proc. Natl. Acad. Sci. USA (Sep. 1988) vol. 85, pp. 6460-6464.

A63

Fuerst, Thomas R., and Moss, Bernard "Structure and Stability of mRNA Synthesized by Vaccinia Virus-encoded Bacteriophage 17 RNA Polymerase in Mammalian Cells" J. Mol. Biol. (1989) vol. 206, pp. 333-348.

A64

Lieber, Andre, et al., "High Level Gene Expression in Mammalian Cells by a Nuclear 17-Phage RNAPolymerase" Nucleic Acids Research (1989) vol. 17, No. 21, pp. 8485-8493.

A65

Larder, Brendan A., et al., "HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy "Science (Mar. 31, 1989) vol. 243, pp.1731-1734.

A66

Andreasson, K.I., et al., "Production of Pro-Opiomelanocortin (POMC) by a Vaccinia Virus Transient Expression System and In Vitro Processing of the Expressed Prohormone by POMC-converting Enzyme" FE.B.S Letters (May 1989) vol. 248, No. 1.2 pp. 43-47.

A67

Elroy-Stein, Orna, et al., "Cap-Independent Translation of mRNA Conferred by Encephalomyocarditis Virus 5' Sequence Improves the Performance of the Vaccinia Virus/ Bacteriophage T7 Hybrid Expression System" Proc. Natl. Acad. Sci. USA (Aug. 1989) vol. 86, pp. 6126-6130.

A68

Larder, Brendan A., and Sharon D.Kemp, "Multiple Mutations in HIV-1 Reverse Transcriptase confer High-Level Resistance of Zidovudine (AZT)" Science (Dec. 1089) vol. 246, pp. 1155-1158.

A69

Elroy-Stein, Orna and Bernard Moss, "Cytoplasmic Expression System Based on Constructive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells" Proc. Natl. Acad. Sci. USA (Spe. 1990) vol. 87, pp. 6743-6747.

A70

Page, Kathleen A., et al., "Construction and Use of a Human Immunodeficiency Virus Vector for Analysis of Virus Infectivity" Journal of Virology (Nov. 1990) vol. 64, No. 11, pp. 5270-5276.

A71

Moss, B et al., "New Mammalian Expression Vectors" Nature (Nov. 1990) vol. 348, pp. 91-92.

A72

Deng, Hong, et al., "High-Efficiency Protein Synthesis from T7 RNA Polymerase Transcripts in 3T3 Fibroblasts" GENE (1991)pp. 193-201.

A73

Goldman, Mark E., et al., "L-696,229 Specifically Inhibits Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Possesses Antiviral Activity In Vitro" Antimicrobial Agents and Chemotherapy (May 1992) vol. 36, No. 5, pp. 1019-1023.

JUN 03 2004
 7 & TRADEMARK OFFICE 190

A74	Saari, Walfred, S., et al. "2-Pyridinone Derivatives: A New Class of Nonnucleoside HIV-1 Spedivid Reverse Transcriptase Inhibitors" Journal of Medicinal Chemistry (1991) vol. 34, No. 9, pp. 2922-2925.
A75	Landau, Nathaniel, R., et al., "Pseudotyping with Human T-Cell Leukemia Virus Type 1 Broadens the Human Immunodeficiency Virus Host Range" Journal of Medicinal Chemistry (1991) vol. 34, No. 9, pp 2922-2925.
A76	Goldman, Mark E., et al., "Pyridinone Derivatives: Specific Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors with Antiviral Activity" Proc. Natl. Acad. Sci. USA (Aug. 1991) vol. 88, pp. 6863-6867.
A77	Nunberg, Jack H., et al., "Viral Resistance to Human Immunodeficiency Virus Type-1 Specific Pyridinone Reverse Transcriptase Inhibitors" Journal of Virology (Sep. 1991) vol. 65, No. 9, pp. 4887-4892.
A78	St. Clair, M.H., et al. "Resistance to ddl and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse transcriptase" Science (Sep. 27, 1991) vol. 253, pp. 1557-1559.
A79	Huang, Mingjun and Summers, Jesse "Infection Initiated by the RNA Pregenome of a DNA Virus" Journal of Virology (Oct. 1991) vol. 65, No. 10, pp. 5435-543.
A80	Larder, Brendan, A., et al., "Zidovudine-Resistant Human Immunodeficiency Virus Selected by Passage in Cell Culture" Journal of Virology (Oct. 1991) vol. 65, No. 10, pp. 5232-5236.
A81	Homberger, F. R., et al. "Detection of Rodent Coronaviruses in Tissues and Cell Cultures by Using Polymerase Chain Reaction" J. Clin. Microbiol. (Dec. 1991) vol. 29:2789-2793.
A82	Sardana, Vinod, V, et al., "Functional Analysis of HIV-1 Reverse Transcriptase Amino Acids Involved in Resistance to Multiple Nonnucleoside Inhibitors" Journal of Biological Chemistry (1992) vol. 267, No. 25, pp. 17526-17530.
A83	Yang, Xian-Cbeng, et al., "Cell-Specific Posttranslational Events Affect Functional Expression at the Plasma Membrane but not Tetrodotoxin Sensitivity of the Rat Brain VIA Sodium Channel α -Subunit Expressed in Mammalian Cells" The Journal of Neuroscience (Jan. 1992) vol. 12(1), pp. 268-277.
A84	Richman, Douglas D. "Antiretroviral Drug Resistance: Mechanisms, Pathogenesis, Clinical Significance" pp. 1-13.
A85	Condra, Jon H., et al., "Identification of the Human Immunodeficiency Virus Reverse Transcriptase Residues That Contribute to the Activity of Diverse Nonnucleoside Inhibitors" Antimicrobial Agents and Chemotherapy (Jul. 1992) vol. 36, No. 7, pp. 1441-1446.
A86	Trono, Didier, "Partial Reverse Transcripts in Virions from Human Immunodeficiency and Murine Leukemia Viruses" Journal of Virology (Aug. 1992) vol. 66, No. 8, pp. 4893-4900.
A87	Lori, Franco, et al., "Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions" Journal of Virology (Aug. 1992) vol. 66, No. 8, pp. 5067-5074.
A88	Larder, Brendan A., "3' Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nonnucleoside Reverse Transcriptase Inhibitors" Antimicrobial Agents and Chemotherapy (Dec. 1992) vol. 36, No. 12, pp. 2664-2669.
A89	Gu, Zhengxian, et al., "Novel Mutation in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Encodes Cross-Resistance to 2',3'-Dideoxyinosine and 2', 3'-Dideoxycytidine" Journal of Virology (Dec. 1992) vol. 66, No. 12, pp. 7128-7135.
A90	Baltimore, David, "The Treasure Under the Right Stone" Reverse Transcriptase (1993) pp. 1-3
A91	Larder, Brendan A., "Inhibitors of HIV Reverse Transcriptase as Antiviral Agents and Drug Resistance" Chapter 11 Reverse Transcriptase pp. 205-222 Cold Spring Harbor Laboratory Press (1993).
A92	Gao, Xiang, and Huang, Leaf, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes" Nucleic acids Research (1993) vol. 21, No. 12, pp. 267-2872.
A93	Gottesman, Michael M., and Pastan, Ira, "Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter" Annu. Rev. Biochem. (1993) vol. 62, pp. 385-427
A94	Le Grice, Stuart FJ., "Human Immunodeficiency Virus Reverse Transcriptase" Reverse Transcriptase (1993) pp. 163-191.
A95	Telesnitsky, Alice and Goff, Stephen P., "Strong-stop Strand transfer during Reverse Transcription" Reverse Transcriptase (1993) pp. 49-83.


A96	Wlodawer, Alexander and Erickson, John W., "Structure Based Inhibitors of HIV-1 1 Protease" Annu. Rev. Biochem. (1993) vol. 62, pp. 543-585.
A97	Richman, Douglas D., "HIV Drug Resistance" Annu. Rev. Pharmacol. Toxicol. (1993) vol. 32, pp. 149-164.
A98	Sandig, Volker, et al., "A Phage T7 Class-III Promoter Functions as a Polymerase II Promoter in Mammalian Cells" GENE (1993) pp. 255-259.
A99	Lieber, Andre, et al., "A Mutant T7 Phage Promoter is Specifically Transcribed by T7-RNA Polymerase in Mammalian Cells" Eur. J. Biochem. (1993) vol. 217, pp. 387-394.
A100	Chattopadhyay, Sisir K., et al., "Genomes of Murine Leukemia Viruses Isolated from Wild Mice" Journal of Virology (Sep. 1981) vol. 39, No. 3, pp. 777-791.
A101	Richman, Douglas D., "Minireview, Resistance of Clinical Isolates of Human Immunodeficiency Virus to Antiretroviral Agents" Antimicrobial Agents and Chemotherapy (June 1993) vol. 37, No. 6, pp. 1207-1213.
A102	Richardson, Jennifer H., et al., "Packaging of Human Immunodeficiency Virus Type 1 RNA Requires cis-Acting Sequences Outside the 5' Leader Region" Journal of Virology (July 1993) vol. 67, No. 7, pp. 3997-4005.
A103	Byrnes, Vera W., et al., "Comprehensive Mutant Enzyme and Viral Variant Assessment of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Nonnucleoside Inhibitors" Antimicrobial Agents and Chemotherapy (Aug. 1993) vol. 37, No. 8, pp. 1576-1579.
A104	Emmini, Emilio A., et al., "HIV-1 Error Revealed" Nature (Aug. 19, 1993) vol. 364, pp. 679.
A105	Balzarini, Jan et al., "Treatment of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells with Combinations of HIV-1-Specific Inhibitors Results in a Different Resistance Pattern Than Does Treatment with Single-Drug Therapy" Journal of Virology (Sep. 1993) vol. 67, No. 9, pp. 5353-5359.
A106	Larder, Brendan A., et al., "Convergent Combination Therapy can Select Viable Multidrug-Resistant HIV-1 In Vitro" Nature (Sep. 30, 1993) vol. 365, pp. 451-453.
A107	Sag, Michael S., et al., "A short Term Clinical Evaluation of L-697,661, A Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase" The New England Journal of Medicine (Oct. 7, 1993) vol. 329, No. 15, pp. 1065-1072.
A108	Boyer, Paul L. et al., "Mutational Analysis of the Fingers and Palm Subdomains of Human Immunodeficiency Virus Type-1 (HIV-1) Reverse Transcriptase" J. Mol. Biology (1994) vol. 243, pp. 472-483.
A109	Deng, Hong, and Wolff, Jon A., "Self-Amplifying Expression from the 17 Promoter in 3D Mouse Fibroblasts" GENE (1994) pp. 245-249.
A110	Richman, Douglas D., "Resistance, Drug Failure, and Disease Progression" AIDS research and Human Retroviruses (1994) vol. 10, No. 8, pp. 901-905.
A111	Ansari-Lari, M. Ali and Gibbs, Richard A., "Analysis of HIV Type 1 Reverse Transcriptase Expression in a Human Cell Line" AIDS Research and Human Retroviruses (1994) vol. 10, No. 9, pp. 1117-1124.
A112	Mirochnitchenki, Oleg, et al., "Production of Single-Stranded DNA in Mammalian Cells by Means of a Bacterial Retron" The Journal of Biological Chemistry (Jan. 1994) vol. 269, No. 4, pp. 2380-2383.
A113	Katz, Richard A., and Skalka, Anna Marie "The Retroviral Enzymes" Annu. Rev. Biochem. (1994) vol. 63, pp. 133-173.
A114	Chen, Xiaozhuo, et al., "A Self-Initiating Eukaryotic Transient Gene Expression System Based on Cotransfection of Bacteriophage T7 RNA Polymerase and DNA Vectors Containing a T7 Autogene" NucleicAcids Research (1994) vol. 22, No. 11, pp. 2114-2120.
A115	Kellam, Paul, et al., "Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance" Journal of General Virology (1994) vol. 75, pp. 341-351.
A116	Kellam, Paul, and Larder, Brendan A., "Recombinant Virus Assay: a Rapid, Phenotypic Assay for Assissment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates" Antimicrobial Agents and Chemotherapy (1994) vol. 38, No. 1, pp. 23-30.
A117	El-Farrash, Mohamed A., et al., "Generation and Characterization of a Human Immunodeficiency Virus Type 1 (HIV-1) Mutant Resistant to an HIV-1 Protease Inhibitor" Journal of Virology (Jan. 1994) vol. 68, No. 1, pp. 233-239.

JUN 03 2004

A118	Chen, Benjamin K., et al., "Distinct Modes of Human Immunodeficiency Virus Type 1 Retroviral Latency Revealed by Superinfection of Nonproductively Infected Cell Lines with Recombinant Luciferase Encoded Viruses" Journal of Virology (Feb. 1994) vol. 68, No. 2, pp. 654-660.
A119	Richman, Douglas D., et al., "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected During Therapy" Journal of Virology (Mar. 1994) vol. 68, pp. 1660-1666.
A120	Ho, David D., et al., "Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to a C ₂ -Symmetric Protease Inhibitor" Journal of Virology (Mar. 1994) vol. 68, No. 3, pp. 2016-2020.
A121	Boyer, Paul L. et al., "Sensitivity of Wild-Type Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Dideoxynucleotides Depends on Template Length; The Sensitivity of Drug-Resistant Mutants Does Not" PNAS (May 1994) vol. 91, pp. 4882-4886.
A122	Brynes, Vera W., et al. "Susceptibilities of Human Immunodeficiency Virus Type 1 Enzyme and Viral Variants Expressing Multiple Resistance-Engendering Amino Acid Substitutions to Reverse Transcriptase Inhibitors" Antimicrobial Agents and Chemotherapy (Jun. 1994) vol. 38, No. 6, pp. 1404-1407.
A123	Parolin, Cristina, et al., "Analysis in Human Immunodeficiency Virus Type 1 Vectors of cis-Acting Sequences That Affect Gene Transfer into Human Lymphocytes" Journal of Virology (Jun. 1994) vol. 68, No. 6, pp. 3888-3895.
A124	Carroll, Richard, et al., "A Human Immunodeficiency Virus Type 1(HIV-1)-Based Retroviral Vectors System Utilizing Stable HIV-1 Packaging Cell Lines" Journal of Virology (Sep. 1994) vol. 68, No. 9, pp. 6047-6051.
A125	Richman, Douglas D., "Drug Resistance in Viruses" Trends in Microbiology (Oct. 10, 1994) vol. 2, No. 10, pp. 401-408.
A126	Zhang, Hui, et al., "Intravirion Reverse Transcripts in the Peripheral Blood Plasma of Human Immunodeficiency Virus Type 1-Infected Individuals" Journal of Virology (Nov. 1994) vol. 68, No. 11, pp. 7591-7597.
A127	Kalderon, Daniel, et al., "A Short Amino Acid Sequence Able to Specify Nuclear Location" Cell (Dec. 1984 - Part 2) vol. 39, pp. 499-509.
A128	Ho, David D. "Time to Hit HIV, Early and Hard" The New England Journal of Medicine (1995) vol. 333, No. 7, pp. 450-451.
A129	Wyatt, Linda S., et al., "Replication-Deficient Vaccinia Virus Encoding Bacteriophage T7 RNA Polymerase for Transient Gene Expression in Mammalian Cells" Virology (1995) vol. 210, pp. 202-205.
A130	Ward, George A., et al., "Stringent Chemical and Thermal Regulation of Recombinant Gene Expression by Vaccinia Virus Vectors in Mammalian Cells" Proc. Natl. Acad. Sci. USA (1995) pp. 6773-6777.
A131	Wei, Xiping, et al., "Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection" Nature Pan. 1995) vol. 373, pp. 117-122.
A132	Richman, Douglas D., "Drug Resistance in Relation to Pathogenesis" AIDS (1995) vol. 9 (Suppl A) pp. S49-S53.
A133	Volberding, Paul, "The Need for Additional Options in the Treatment of Human Immunodeficiency Virus Infection" The Journal of Infectious Diseases (1995) vol. 17 (Suppl 2) pp. S150-S154.
A134	Coffin, John M. "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy" Science (Jan. 27, 1995) vol. 267, pp. 483-489.
A135	Kim Baek and Loeb Lawrence, A "Human Immunodeficiency Virus Reverse Transcriptase Substitutes for DNA Polymerase in Escherichia Coli" P.N.A.S. I vol. 92, pp. 684-688.
A136	Wain-Hobson, Simon "Virological Mayhem" Nature (Jan. 1995) vol. 373, p. 102.
A137	Ho, David D., et al., "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection" Nature (Jan. 1995) pp. 123-126.
A138	D'Aquila, Richard T., et al., "Zidovudine Resistance and HIV-1 Disease Progression During Antiretroviral Therapy" Annals of Internal Medicine (Mar. 15, 1995) vol. 122, No. 6, pp. 401-408.
A139	Condra, John H., et al., "In Vivo Emergence of HIV-1 Variants Resistant to Multiple Protease Inhibitors" Nature (Apr. 6, 1995) vol. 374, pp. 569-571.

A140	Boyer, Paul L., and Hughes, Stephen H., "Analysis of Mutations at Position 184 in Reverse Transcriptase of Human Immunodeficiency Virus Type 1" Antimicrobial Agents and Chemotherapy (Jul. 1995) vol. 39, No. 7, pp. 1624-1628.
A141	He, Jianglin, and Landau, Nathaniel R., "Use of a Novel Human Immunodeficiency Virus Type 1 Reporter Virus Expressing Human Placental Alkaline Phosphatase To Detect an Alternative Viral Receptor" Journal of Virology (Jul. 1995) vol. 69, No. 7, pp. 4587-4592.
A142	Kim, Baek and Loeb, Lawrence A., "A Screen in Escherichia coli for Nucleoside Analogs That Target Human Immunodeficiency Virus (HIV) Reverse Transcriptase: Coexpression of HIV Reverse Transcriptase and Herpes Simplex Virus Thymidine Kinase" Journal of Virology (Oct. 1995) vol. 69, No. 10, pp. 6563-6566.
A143	Saunders, J., and Cameron, J.M., "Recent Development in the Design of Antiviral Agents" Med Res. Rev. (Nov. 1995) vol. 15:497-531.
A144	Young, Steven D., et al., "L-743,726 (DMP-266): a Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase" Antimicrobial Agents and Chemotherapy (Dec. 1995) vol. 39, No. 12, pp. 2602-2605.
A145	Goldman, Mark E., et al., "A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors!" Antimicrobial Agents and Chemotherapy (May 1993) vol 37, No. 5, pp. 947-949.
A146	Fang, Guowei, et al., "Molecular Cloning of Full-Length HIV-1 Genomes Directly from Plasma Viral RNA" Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (1996) vol. 12, No. 4, pp. 352-357.
A147	Heid, Christian A., et al., "Real Time Quantitative PCR" Genome Research (1996) pp. 986-994.
A148	Romeyn, Mary, "Report from the 3rd Conference of Retroviruses and Opportunistic Infections" BETA (Mar. 1996).
A149	Schapiro, Jonathan, M., "Causes of Long Term Efficacy and/or Drug Failure in Protease (PR) Inhibitor Monotherapy" ICA Abstracts.
A150	Mamatora, Gargi, et al., "HIV-1 Genechip™ and Dideoxynucleotide Sequence Analysis of HIV-1 Genomes Present in Plasma Samples from Patients of ACTG 143 Study" ICA Abstracts.
A151	Garrett, Miyada, C., et al., "Sequencing HIV Isolates Using the Genechip™ HIV PRT Assay" ICA Abstracts.
A152	Gingeras, Thomas R., et al. "Detection of Rifampin Conferring Mutations and Mycobacteria Speciation Using Myco Genechip™" ICA Abstracts.
A153	Fischl, Margaret A., "Treatment of HIV Infection" Section II-Management of HIV Infections and Their Complications, Chapter 8, pp. 141-160.
A154	Saag, Michael S. "AIDS Testing Now and in the Future" Section I-The Virus: Its Transmission and Infection, Chapter 4, pp. 65-88, 1994.
A155	Richman, Douglas, D., "Antiviral Drug Resistance: Issues and Challenges" Antiviral Drug Resistance, Introductory Chapter, pp. 1-19.
A156	Japour, Anthony J., "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 isolates" Antimicrobial Agents and Chemotherapy (May 1993) vol. 37, pp. 1095-1101.
A157	Pauwels, Rudi, et al. "Rapid and Automated Tetrazoliumbased Colorimetric Assay for the Detection of anti-HIV Compounds" Journal of Virological Methods (1988) vol. 20, pp. 309-321.
A158	Larder, B. A., (1994) " Interactions Between Drug Resistance Mutations In Human Immunodeficiency Virus Type 1 Reverse Transcriptase" Journal of General Virology, 75:951-957.
A159	Piatak, Jr., M., et al. (1993) "High Levels of HIV-1 In Plasma During All Stages Of Infection Determined By Competitive PCR" Science 259:1749-1754.
A160	Popovic, M., et al. (1984) "Detection, Isolation, and Continuous Production Of Cytopathic Retroviruses (HTLV-III) From Patients With AIDS And Pre-AIDS" Science, 224:497-500.
A161	Saltarelli, M. J., et al. (1993) "The CAEV tat Gene Transactivates The Viral LTR And Is Necessary For Efficient Viral Replication" Virology, 197:35-44.
A162	Urdea, M. S., (1993) "Synthesis And Characterization of Branched DNA (bDNA) For The Direct And Quantitative Detection Of CMV, HBV, HCV, and HIV" Clin. Chem. 39:725-726.

JUN 03 2004



A163	Allain, J., et al. (1987) "Long-Term Evaluation Of HIV Antigen And Antibodies To p24 And gp41 In Patients With Hemophilia" N. EngL J. Med., 317:1114-1121.
A164	Barre-Sinoussi, F. et al. (1983) "Isolation Of A T-Lymphotropic Retrovirus From A Patient At Risk For Acquired Immune Deficiency Syndrome (AIDS)" Science 220:868-871.
A165	Geodert, J. J., et al. (1987) "Effect Of T4 Count And Cofactors On The Incidence Of AIDS In Homosexual Men Infected With Human Immunodeficiency Virus", Jama 257:331-334.
A166	Database Medline, US Nat. Lib., No. 97151131, Filocamo, G. et al. "Chimeric Sindbis Viruses dependent on NS3 protease of hepatitis C virus" J of Virology, (1997) 71(2):1117-27.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.